On January 27th, Eurofins Central Laboratory recognizes World Leprosy Day with the World Health Organization (WHO). Also known as Hansen’s disease, Leprosy is a chronic infectious disease caused by Mycobacterium Leprae. This disease affects the skin, peripheral nerves, mucus membranes of the upper respiratory tract, and eyes. Individuals affected will experience sensory loss in these affected areas as well as damaged thickened nerves.
Leprosy is curable , and undergoing early treatment is proven to prevent disabilities.
For treatment, the WHO recommends using multi-drug therapy, with Rifampicin being the most important, as well as Clofazimine and Dapsone. The numbers of new leprosy cases reported globally were:
- 215,656 cases in 2013
- 213,899 cases in 2014
- 211,973 cases in 2015
At Eurofins Central Laboratory, we are delighted to continuously view a decrease in new cases of this disease per year. Biomarkers such as IFN-Y or IP-10, MCP-1, MIP-1beta, and IL-1beta can determine immune responses from those exposed to Mycobacterium Leprae.
We offer exploratory and confirmatory biomarker analysis globally in our 4 CAP-accredited locations - including the United States, Europe, Singapore and China - like IFN-Y, IP-10, MCP-1, MIP-1beta, and IL-1beta. For modern global clinical trials, utilizing disease-related biomarkers as surrogate endpoints is standard practice. Harmonization and standardization across all laboratory locations is critical for the validity of biomarker utilization.
Further, Eurofins Central Laboratory is uniquely positioned with the Biomarker Center of Excellence by uniting GLP and GCP in one synergetic approach, as well as being supported by an industry-leading scientific team.
Please reach out to us to learn more about how our biomarker assays are developed and fit-for-purpose validated to meet the specific requirements of your clinical trial program.